Tamara Thomas

Urban Health Today

Treating diabetes-related eye disease early might slow its progression to severe disease, but it does not improve visual acuity compared with treating the condition once developed, according to a study published in JAMA.Anti-vascular endothelial growth factor (anti-VEGF) has been shown to decrease the risk of vision loss from diabetic retinopathy significantly. However, eye specialists are unsure when treatment with anti-VEGF should start to achieve the best long-term outcome.Dr. Raj Maturi and colleagues conducted a study to find out whether using the medication aflibercept to treat patients with nonproliferative diabetic retinopathy (NPDR) and good vision would reduce disease progression and improve long-term visual acuity compared to only treating if the disease worsens.The study included 328 participants, with 399 study eyes (both eyes in some participants met the enrollment criteria; others only had one study-eligible eye). The researchers randomly assigned the participants to receive injections with preventive anti-VEGF (aflibercept) or a placebo solution, then followed them for up to four years.&nbsp;Preventive therapy was injected into 200 eyes, while 199 were given a placebo. The preventive therapy was given every four months, except in cases where the NPDR improved to only mild disease.At the end of the study, the researchers found that the group who received the anti-VEGF had less structural damage to the eye than those who received the placebo. In addition, they found that disease progression was lower in the group receiving anti-VEGF injections compared with the placebo group (37% vs 54%). However, the drug did not do much to prevent vision loss.&ldquo;We expected early treatment to prevent progression of diabetic retinopathy, but even with preventative injections, about one-third of eyes developed vision-threatening complications,&rdquo; said Adam Glassman, who directs the DRCR Retina Network coordinating center.According to one of the senior authors, the study findings indicate that the benefit of anti-VEGF treatment may not be worth the &ldquo;risk and inconvenience&rdquo; of repetitive visits for preventive NPDR injections.&nbsp;Source:<a href="https://www.nih.gov/news-events/news-releases/early-anti-vegf-treatment-diabetic-retinopathy-yields-no-benefit-visual-acuity"> NIH Newsletter</a>

Payton White, BS

How Sleep Quality Influences Risk of Alzheimer’s Disease

Alzheimer's & Dementia

Lou Portero

Hidden Dangers: The Blood Sugar Crisis in Modern Breast Cancer Treatment

Diabetes in Women

New ACG Guidelines Address Critical Gastric Cancer Disparities in Non-White Americans

Gastroenterology

Latest News

Early Anti-VEGF Treatment for Diabetic Retinopathy Not Beneficial to Visual Acuity

Eye Disease

“We expected early treatment to prevent progression of diabetic retinopathy, but with preventative injections, about one-third of eyes developed vision-threatening complications."

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe